Utility of the Lung Immune Prognostic Index (LIPI) in prognostication and disease control prediction in advanced NSCLC patients treated with nivolumab.

Juan Ruiz-Bañobre,María Carmen Areses Manrique,Rosario García-Campelo,Rafael López,F.J. Afonso,Joaquin Casal Rubio,Sergio Vázquez Estévez,Cristina Azpitarte-Raposeiras,Margarita Amenedo,Lucía Santomé,José Luis Fírvida Pérez,Joaquín Martínez,Alexandra Cortegoso,Rocío Vilchez Simo,Gerardo Huidobro Vence,Natalia Fernández Núñez,Nazaret Quiroga Veiga,Jesús García Mata,Guillermo Alonso-Jaudenes Curbera,Urbano Anido Herranz

Utility of the Lung Immune Prognostic Index (LIPI) in prognostication and disease control prediction in advanced NSCLC patients treated with nivolumab.

2019

e20645Background: The lung immune prognostic index (LIPI) has been proposed as a new biomarker to select advanced non-small cell lung cancer (NSCLC) patients for anti-programmed cell death-1 or pro...

Keywords:

Nivolumab
Pathology
Immune system
Disease
Oncology
Medicine
Lung
Internal medicine
Biomarker (medicine)
Cell
non small cell
disease control

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations